BiotechTube

Placebo + lorundrostat Dose 1 + lorundrostat Dose 2

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertension

Conditions

Hypertension

Trial Timeline

Nov 22, 2023 → Jan 24, 2025

NCT ID
NCT06153693

About Placebo + lorundrostat Dose 1 + lorundrostat Dose 2

Placebo + lorundrostat Dose 1 + lorundrostat Dose 2 is a phase 3 stage product being developed by Mineralys Therapeutics for Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT06153693. Target conditions include Hypertension.

What happened to similar drugs?

20 of 20 similar drugs in Hypertension were approved

Approved (20) Terminated (1) Active (0)
✅Tirzepatide + Tirzepatide PlaceboEli LillyApproved
✅Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
✅Amlodipine + ValsartanYuhanApproved
✅Duowell® + TelmisartanYuhanApproved
✅Olmesartan medoxomil + Losartan potassium + AtenololDaiichi SankyoApproved
✅olmesartan medoxomil + hydrochlorothiazide, if necessary + PlaceboDaiichi SankyoApproved
✅olmesartan medoxomil and a CCB + olmesartan medoxomil and a diureticDaiichi SankyoApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06153693Phase 3Completed
NCT05769608Phase 2Completed

Competing Products

20 competing products in Hypertension

See all competitors
ProductCompanyStageHype Score
macitentan 10 mgBML, Inc.Phase 3
32
tadalafil + tadalafilEli LillyPhase 3
40
CS1 AdministrationCereno ScientificPhase 2
29
CS1Cereno ScientificPre-clinical
24
TX000045- Dose A + TX000045- Dose B + PlaceboTectonic TherapeuticPhase 2
36
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeksKeros TherapeuticsPhase 2
25
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
50
L04RD1 + L04TD3CelltrionPhase 1
29
Azilsartan MedoxomilCelltrionPre-clinical
26
AZM X mg + AML Y mg + AZM X mg + AML Y' mg + AZM X' mg + AML Y mg + AZM X' mg + AML Y' mg + AZM X mg + AZM X' mg + AML Y mg + AML Y' mgCelltrionPhase 3
40
Satralizumab (Genetical Recombination)Chugai PharmaceuticalPhase 2
39
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgYuhanApproved
47
Telmisartan + Amlodipine + ChlorthalidoneYuhanPhase 1
29
Temisartan/Amlodipine+Rosuvastatin + YHP1604YuhanPhase 1
29
Temisartan+Amlodipine+Rosuvastatin (Combination drug) + Temisartan+Amlodipine + Temisartan+RosuvastatinYuhanPhase 3
40
Amlodipine + ValsartanYuhanApproved
43
Duowell® + TelmisartanYuhanApproved
43
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
40
YH22189 + Twynsta 80/10mg + Crestor 20mgYuhanPhase 1
21
OM 40 + OM/HCTZ 40/12.5Daiichi SankyoPhase 3
40